GPR35 and colonic neoplasm: We have previously shown that treatment of wild-type mice with a GPR35-selective, inhibitory pepducin (g35i2) reduced the number of inflammatory colon tumours.10 In the AOM/DSS model, the number of macroscopically visible tumours in g35i2-treated wild-type mice decreased fivefold, whereas the number of microscopic tumours decreased only threefold (figure 6F).